New drugs: milnacipran hydrochloride, fesoterodine fumarate, and silodosin.
Hussar
Daniel A
DA
Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, USA.
D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003521:Cyclopropanes / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D005356:Fibromyalgia / Q000188:drug therapy / Q000378:metabolism; D006801:Humans; D007211:Indoles / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D008297:Male; D000078764:Milnacipran; D018727:Muscarinic Antagonists / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000188:drug therapy / Q000378:metabolism; D053201:Urinary Bladder, Overactive / Q000188:drug therapy / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D001559:Benzhydryl Compounds; D003521:Cyclopropanes; D007211:Indoles; D018727:Muscarinic Antagonists; C526675:fesoterodine; C095285:silodosin; D000078764:Milnacipran